Oklo Inc vs Smith & Nephew plc — how do they compare? Oklo Inc trades at $44.41 (market cap $7.68B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.59% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| OKLO | SNN | |
|---|---|---|
Market Cap | $7.68B | $12.71B |
Sector | Technology | Health |
52-Week High | $174.14 | $38.70 |
52-Week Low | $41.11 | $28.73 |
Enterprise Value | $5.47B | $15.48B |
Dividend Yield | — | 2.59% |
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $41.51, up 0.97% today but remains in a significant downtrend with a 42% decline year-to-date. The stock shows bearish technical signals with negative profitability metrics including -8.87% ROE and consistent quarterly losses. Recent news highlights participation in a government nuclear power program for AI data centers, providing potential catalysts amid ongoing regulatory challenges and execution risks.
Despite analyst optimism with a $90.88 consensus target representing 119% upside, OKLO faces substantial execution and regulatory hurdles. The company burns significant cash with -$138.77M EBITDA while relying on financing activities. Long-term potential exists in nuclear energy demand, but near-term volatility and losses require careful risk assessment for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →